Clinical Translation of Hybrid Treg/Th2 (RAPA501) Cells for Therapy of ALS
Time: 2:30 pm
day: Conference Day One Track B PM
Details:
- Mechanism of action of RAPA501
- Phase 1 results; manufacturing, safety and immune modulation
- Implementing 40 patient Expanded Access trial (<50% pulmonary function)
- Implementing Phase 2/3 trial (>70% pulmonary function)
